ERBB2 and breast carcinoma: Neratinib has been recently approved by United States FDA for use in early stage HER2-overexpressed/amplified breast cancer (Bose and Ozer, 2009; Feldinger and Kong, 2015; Kourie et al., 2016; US Food and Drug Administration, 2018).